---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-106619"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:49:16.430318+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Sarepta appoints Deirdre Connelly to board, increases board size to 9

## Summary
- Deirdre Connelly appointed as Class I director effective Sept. 12, 2024, term through 2026 annual meeting.
- Initial equity grant of $712,500 in value, split equally between RSUs and stock options.
- Equity vests in three equal annual installments starting Sept. 12, 2025; annual cash retainer $60,000.
- Board amended bylaws to increase maximum director limit from 8 to 9, effective immediately.

## SEC filing metadata
- accession: 0000950170-24-106619
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000095017024106619/0000950170-24-106619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000095017024106619/srpt-20240912.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-106619
- JSON: https://secwatch.observer/filing/0000950170-24-106619.json
- Plain text: https://secwatch.observer/filing/0000950170-24-106619.txt

## Key facts
- Executive change
  Deirdre Connelly was appointed as Director at Sarepta Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On September 12, 2024, the board of directors (the “ Board ”) of Sarepta Therapeutics, Inc. (the “ Company ”) appointed Deirdre Connelly as a director of the Company, effective immediately, to serve as a member of Class I until the 2026 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000095017024106619/0000950170-24-106619-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.